These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 17054247)

  • 1. Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke.
    Ciccone A; Abraha I; Santilli I
    Cochrane Database Syst Rev; 2006 Oct; (4):CD005208. PubMed ID: 17054247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke.
    Ciccone A; Motto C; Abraha I; Cozzolino F; Santilli I
    Cochrane Database Syst Rev; 2014 Mar; (3):CD005208. PubMed ID: 24609741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycoprotein IIb/IIIa antagonists in acute ischaemic stroke: current status and future directions.
    Mandava P; Thiagarajan P; Kent TA
    Drugs; 2008; 68(8):1019-28. PubMed ID: 18484795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation.
    Ibbotson T; McGavin JK; Goa KL
    Drugs; 2003; 63(11):1121-63. PubMed ID: 12749745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in the management of ischemic stroke.
    Lapchak PA; Araujo DM
    Am J Cardiovasc Drugs; 2003; 3(2):87-94. PubMed ID: 14727935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of abciximab in patients with acute myocardial infarction and failed thrombolysis.
    Di Pasquale P; Cannizzaro S; Scalzo S; Maringhini G; Vitrano GM; Giubilato A; Giambanco F; Sarullo FM; Paterna S
    Int J Cardiol; 2003 Dec; 92(2-3):265-70. PubMed ID: 14659863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy of intravenous glycoprotein IIB/IIIA inhibitors and tissue plasminogen activator for acute ischemic stroke.
    Dubey D; Banerjee C; Sawhney A; Sharma A; Alberts MJ
    Neurol India; 2014; 62(6):631-4. PubMed ID: 25591675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
    Bosch X; Marrugat J; Sanchis J
    Cochrane Database Syst Rev; 2013 Nov; (11):CD002130. PubMed ID: 24203004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
    Gurm HS; Tamhane U; Meier P; Grossman PM; Chetcuti S; Bates ER
    Circ Cardiovasc Interv; 2009 Jun; 2(3):230-6. PubMed ID: 20031720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet therapy for acute ischaemic stroke.
    Sandercock PA; Counsell C; Gubitz GJ; Tseng MC
    Cochrane Database Syst Rev; 2008 Jul; (3):CD000029. PubMed ID: 18646056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracoronary use of GP IIb/IIIa inhibitors in percutaneous coronary interventions.
    De Vita M; Coluccia V; Burzotta F; Romagnoli E; Trani C
    Curr Vasc Pharmacol; 2012 Jul; 10(4):448-53. PubMed ID: 22339256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
    Ibbotson T; McGavin JK; Goa KL
    Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
    Bosch X; Marrugat J; Sanchis J
    Cochrane Database Syst Rev; 2010 Sep; (9):CD002130. PubMed ID: 20824831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
    Bosch X; Marrugat J; Sanchis J
    Cochrane Database Syst Rev; 2013 Oct; (10):CD002130. PubMed ID: 24136036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases.
    Chong PH
    Am J Health Syst Pharm; 1998 Nov; 55(22):2363-86. PubMed ID: 9825033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty.
    Haase KK; Mahrholdt H; Schröder S; Baumbach A; Oberhoff M; Herdeg C; Karsch KR
    Am Heart J; 1999 Feb; 137(2):234-40. PubMed ID: 9924156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis.
    Dasgupta H; Blankenship JC; Wood GC; Frey CM; Demko SL; Menapace FJ
    Am Heart J; 2000 Aug; 140(2):206-11. PubMed ID: 10925331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis.
    Montalescot G; Borentain M; Payot L; Collet JP; Thomas D
    JAMA; 2004 Jul; 292(3):362-6. PubMed ID: 15265852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advancing the battle against acute ischemic syndromes: a focus on the GP IIb-IIIa inhibitors.
    Dobesh PP; Latham KA
    Pharmacotherapy; 1998; 18(4):663-85. PubMed ID: 9692642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.